A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
Empassion
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy
2 other identifiers
interventional
115
24 countries
106
Brief Summary
The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months. More information can be found here: https://clinicaltrials.argenx.com/empassion
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3
Started Dec 2024
Longer than P75 for phase_3
106 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 16, 2024
CompletedStudy Start
First participant enrolled
December 18, 2024
CompletedFirst Posted
Study publicly available on registry
December 19, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2029
March 13, 2026
March 1, 2026
1.7 years
December 16, 2024
March 11, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change from baseline in grip strength (3-day moving average) in the most affected hand at week 24
Up to 24 weeks
Secondary Outcomes (21)
Change from baseline in MMN-RODS centile score at week 24
Up to 24 weeks
Change from baseline in mMRC-14 sum score
Up to 24 weeks (Part A), Up to 120 weeks (Part B)
PGI-C actual value
Up to 24 weeks (Part A), Up to 120 weeks (Part B)
Change from baseline in CAP-PRI total score
Up to 24 weeks (Part A), Up to 120 weeks (Part B)
Percentage change from baseline in time to complete the 9-HPT with the dominant hand
Up to 24 weeks (Part A), Up to 120 weeks (Part B)
- +16 more secondary outcomes
Study Arms (3)
Part A - empasiprubart + IVIg-placebo
EXPERIMENTALDuring the double blinded - double dummy part A, participants receive empasiprubart and a placebo resembling the IVIg treatment in this arm
Part A - IVIg + empasiprubart-placebo
ACTIVE COMPARATORDuring the double blinded - double dummy part A, participants receive IVIg and a placebo resembling the empasiprubart treatment in this arm
Part B - empasiprubart
EXPERIMENTALAfter completion of part A, participants can proceed to part B where they receive empasiprubart (no IVIg)
Interventions
Intravenous infusion of empasiprubart
Intravenous infusion of IVIg
A placebo resembling the empasiprubart treatment
Eligibility Criteria
You may qualify if:
- Is at least 18 years of age and the local legal age of consent for clinical studies
- Has a confirmed diagnosis of definite or probable MMN at screening according to the EFNS/PNS 2010 guidelines
- Has responded to IVIg in the past 5 years.
- Is receiving IVIg at a treatment interval of once every 2, 3, 4, or 5 weeks, and a dose of 0.4 to 2.0 g/kg body weight per cycle
- Is receiving a maintenance regimen (no change in frequency, and no change in dose \>10%) of IVIg for at least 8 weeks before screening (or at least 10 weeks for participants receiving IVIg once every 5 weeks)
- Minimum converted weekly IVIg dose of ≥0.125 g/kg
- Has documented immunization against encapsulated bacterial pathogens (N meningitidis and S pneumoniae) within 5 years of screening or is willing to receive immunization at least 14 days before first study drug administration
You may not qualify if:
- Besides the indication under study, known autoimmune disease (eg, SLE) or any other medical condition that would confound the study results or put the participant at undue risk
- Clinical signs or symptoms suggestive of neuropathies other than MMN, such as motor neuron disease (eg, bulbar signs, brisk reflexes) or other inflammatory neuropathies (eg, sensory neuropathy)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- argenxlead
Study Sites (109)
HonorHealth Neurology - Bob Bove Neuroscience Institute - Neurology
Scottsdale, Arizona, 85251, United States
The Neurology Group
Pomona, California, 91767, United States
Samir Macwan, M.D., Inc.
Rancho Mirage, California, 92270, United States
University of California San Francisco
San Francisco, California, 94143, United States
University of Colorado - Anschutz Cancer Pavilion (Neuro Onc Clinic)
Aurora, Colorado, 80045, United States
Yale University School of Medicine
New Haven, Connecticut, 06511, United States
Medstar Health Research Institute
Washington D.C., District of Columbia, 20010, United States
EZR Research LLC
Boca Raton, Florida, 33486, United States
Healthcare Innovations Institute, LLC
Coral Springs, Florida, 33067, United States
University of Miami Miller School of Medicine
Miami, Florida, 33136, United States
University of South Florida
Tampa, Florida, 33612, United States
Northwestern University
Chicago, Illinois, 60611, United States
Indiana University Health Neuroscience Center
Indianapolis, Indiana, 46202, United States
University of Kansas Medical Center
Fairway, Kansas, 66205, United States
Perelman Center for Advanced Medicine
Columbia, Maryland, 21044, United States
UC Irvine - MDA ALS and Neuromuscular Center
Columbia, Maryland, 21044, United States
University of Minnesota
Minneapolis, Minnesota, 55414, United States
Dent Neurologic Institute Amherst
Amherst, New York, 14226, United States
Columbia University Medical Center
New York, New York, 10032, United States
University of North Carolina at Chapel Hill
Morrisville, North Carolina, 27560, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
Oregon Health and Science University
Portland, Oregon, 97239, United States
National Neuromuscular Research Institute
Austin, Texas, 78759-8402, United States
NeuroCarePlus
Houston, Texas, 77094, United States
Royal Melbourne Hospital
Parkville, 3050, Australia
Gold Coast University Hospital
Southport, 4215, Australia
Brain and Mind Center
Sydney, 2609, Australia
Princess Alexandra Hospital
Woolloongabba, 4102, Australia
Universitätsklinikum AKH Wien
Vienna, 1090, Austria
UZ Antwerpen
Edegem, 2650, Belgium
UZ Leuven
Leuven, 3000, Belgium
Hôpital de la Citadelle
Liège, 4000, Belgium
Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto
Ribeirão Preto, 14051, Brazil
Sociedade de Ensino Superior Estacio de Sa Ltda
Rio de Janeiro, 22620-172, Brazil
Escola Bahiana de Medicina e Saude Publica
Salvador, 40290-000, Brazil
PSEG Centro de Pesquisa Clínica
São Paulo, 04038-002, Brazil
Neuro-Outaouais Clinic
Gatineau, J8Y 1W2, Canada
London Health Sciences Centre
London, N6A 5A5, Canada
St. Paul's Neurology Associates
Vancouver, V6Z 2H2, Canada
Huashan Hospital Fudan University
Shanghai, 200040, China
Fakultni nemocnice Brno
Brno, 625 00, Czechia
Fakultni nemocnice Hradec Kralove
Hradec Králové, 500 05, Czechia
Vseobecna Fakultni Nemocnice V Praze
Prague, 128 08, Czechia
Aarhus Universitetshospital
Aarhus, 8200, Denmark
Rigshospitalet-Inge Lehmanns Vej 8
Copenhagen, 2100, Denmark
CHU de Bordeaux - Hôpital Pellegrin
Bordeaux, 33000, France
CHU de Brest - Hôpital La Cavale Blanche
Brest, 29609, France
Hospices Civils de Lyon - Hôpital Pierre Wertheimer
Bron, 69500, France
AP-HP - Hôpital Bicêtre
Le Kremlin-Bicêtre, 94270, France
Hôpital Roger Salengro
Lille, 59000, France
CHU Limoges - Dupuytren 1
Limoges, 87042, France
AP-HM- Hôpital de La Timone
Marseille, 13005, France
AP-HM- Hôpital de La Timone
Marseille, 13385, France
CHU de Nice-Hôpital Pasteur
Nice, 6001, France
AP-HP - Hôpital de la Pitié Salpétrière
Paris, 75013, France
CHU de Strasbourg - Hôpital de Hautepierre
Strasbourg, 67200, France
Universitätsklinikum Essen
Essen, 45147, Germany
Universität Georg August
Göttingen, 37075, Germany
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
Lübeck, 23538, Germany
Universitätsklinikum Münster
Münster, 48149, Germany
Alexianer - MVZ St. Josefs-Krankenhaus Potsdam GmbH
Potsdam, 14471, Germany
Universitätsklinikum Würzburg
Würzburg, 97080, Germany
University General Hospital ''ATTIKON'' - General Hospital of West Attica H AGIA VARVARA
Chaïdári, 124 62, Greece
AHEPA University General Hospital of Thessaloniki
Thessaloniki, 546 36, Greece
Azienda Ospedaliera Universitaria Careggi
Florence, 50134, Italy
Ospedale Policlinico San Martino IRCCS
Genova, 16132, Italy
Fondazione Serena Onlus - Centro Clinico NeMO Brescia
Gussago, 25064, Italy
Az. Ospedaliera Universitaria Policlinico G. Martino
Messina, 98124, Italy
Ospedale San Raffaele S.r.l.
Milan, 20132, Italy
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
Milan, 20133, Italy
Azienda Ospedaliero-Universitaria Sant'Andrea
Roma, 00189, Italy
Fondazione PTV Policlinico Tor Vergata
Roma, 133, Italy
IRCCS Istituto Clinico Humanitas
Rozzano, 20089, Italy
Juntendo University Hospital
Bunkyō City, 113-8431, Japan
Institute of Science Tokyo Hospital
Bunkyō City, 113-8519, Japan
Chiba University Hospital
Chūōku, 260-8677, Japan
National Center of Neurology and Psychiatry
Kodaira, 187-8502, Japan
Nagoya University Hospital
Nagoya, 4668560, Japan
Teikyo University Hospital
tabashi City, 173-8606, Japan
Yamaguchi University Hospital
Ube, 755-0067, Japan
Pauls Stradins Clinical University Hospital
Riga, LV-1002, Latvia
Hospital of Lithuanian University of Health Sciences Kauno klinikos
Kaunas, 50161, Lithuania
Amsterdam UMC
Amsterdam, 1105 AZ, Netherlands
Oslo Universitetssykehus HF, Ullevål
Oslo, 0450, Norway
MICS Centrum Medyczne Bydgoszcz
Bydgoszcz, 85-065, Poland
Centrum Medyczne Neurologia Slaska
Katowice, 40-689, Poland
SP ZOZ Szpital Uniwersytecki w Krakowie
Krakow, 30-688, Poland
Galen Clinic -- Lublin
Lublin, 20--64, Poland
UCK WUM, Centralny Szpital Kliniczny
Warsaw, 02-097, Poland
ULS de Santo António, EPE - Hospital de Santo António
Porto, 4099-001, Portugal
University Clinical Center of Serbia
Belgrade, 11000, Serbia
Univerzitna nemocnica Bratislava
Bratislava, 821 01, Slovakia
Univerzitna nemocnica MARTIN
Martin, 036 59, Slovakia
University Medical Centre Ljubljana
Ljubljana, 1000, Slovenia
Hospital General Universitario Dr. Balmis
Alicante, 03010, Spain
Hospital Universitario Germans Trias i Pujol
Badalona, 08916, Spain
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
Hospital de La Santa Creu i Sant Pau
Barcelona, 08041, Spain
Hospital Universitario de Bellvitge
Barcelona, 08907, Spain
Hospital Clinico San Carlos
Madrid, 28039, Spain
Hospital Universitario de Basurto
Madrid, 48013, Spain
Hospital Quironsalud Malaga
Málaga, 29004, Spain
Hospital Universitario de Donostia
San Sebastián, 8035, Spain
Inselspital - Universitätsspital Bern
Bern, 3010, Switzerland
Queen Elizabeth University Hospital
Glasgow, G51 4TF, United Kingdom
John Radcliffe Hospital
Oxford, OX3 7LE, United Kingdom
Salford Royal Hospital
Salford, M6 8HD, United Kingdom
Royal Hallamshire Hospital
Sheffield, S10 2JF, United Kingdom
Musgrove Park Hospital
Taunton, TA1 5DA, United Kingdom
Related Publications (1)
Caballero-Avila M, Pascual-Goni E, Lleixa C, Martin-Aguilar L, Collet-Vidiella R, Querol L. The changing landscape of primary autoimmune neuropathies. Nat Rev Neurol. 2025 Oct;21(10):544-555. doi: 10.1038/s41582-025-01133-3. Epub 2025 Sep 5.
PMID: 40913126DERIVED
Related Links
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 16, 2024
First Posted
December 19, 2024
Study Start
December 18, 2024
Primary Completion (Estimated)
September 1, 2026
Study Completion (Estimated)
December 1, 2029
Last Updated
March 13, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share